Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pyrintegrin is an β1-integrin agonist that promotes embryonic stem cells' survival. Pyrintegrin can be used as a podocyte-protective agent. Pyrintegrin enhances cell-extracellular matrix adhesion-mediated integrin signaling.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 75.00 | |
2 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 162.00 | |
10 mg | In stock | $ 238.00 | |
25 mg | In stock | $ 458.00 | |
50 mg | In stock | $ 683.00 | |
100 mg | In stock | $ 973.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 177.00 |
Description | Pyrintegrin is an β1-integrin agonist that promotes embryonic stem cells' survival. Pyrintegrin can be used as a podocyte-protective agent. Pyrintegrin enhances cell-extracellular matrix adhesion-mediated integrin signaling. |
In vitro | Pyrintegrin decreases Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation. Pyrintegrin treatment prevents damage-induced decreases in F-actin stress fibers, focal adhesions, and active β1-integrin levels in cultured cells. Pyrintegrin stimulates human adipose stem/progenitor cells (hASCs) to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells increasingly secreting adiponectin, leptin, glycerol, and total triglycerides. Pyrintegrin (0-10 μM; 1 hour; hASCs) treatment inhibits BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner (IC50 of 1.14 μM) [1][2]. |
In vivo | Pyrintegrin induces postnatal adipose tissue formation in vivo of transplanted adipose stem/progenitor cells (ASCs) and recruited endogenous cells. Pyrintegrin decreases peak proteinuria caused by puromycin aminonucleoside-induced nephropathy. Pyrintegrin-treated human adipose stem/progenitor cells (ASCs) in 3D-bioprinted scaffolds, when transplanted in the dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ. Pyrintegrin-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation. Pyrintegrin (10 mg/kg; intraperitoneal injection; once; C57BL/6J mice) treatment protects mice from LPS-induced podocyte foot process effacement and proteinuria. LPS administration decreases the levels of active β1 integrin in the podocytes, which is prevented by cotreatment with Pyrintegrin [1][2]. |
Molecular Weight | 451.54 |
Formula | C23H25N5O3S |
CAS No. | 1228445-38-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (553.66 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pyrintegrin 1228445-38-2 Cytoskeletal Signaling Integrin nephropathy C/EBPα embryonic stem inhibit β1-integrin PPARγ Adipogenic cells Inhibitor podocyte-protective ECM proteinuria inhibitor